Changes in the Company’s Management Board – Appointment of the Management Board for a New Term of Office

Current Report No. 24/2025

Date of preparation: 30 May 2025

Subject: Changes in the Company’s Management Board – Appointment of the Management Board for a New Term of Office

Legal basis: Article 56(1)(2) of the Act on Public Offering – current and periodic information

Content of the report:

The Management Board of Captor Therapeutics S.A., with its registered office in Wrocław (the “Company”), hereby announces that on 30 May 2025, the Company received a resignation statement from Mr. Thomas Shepherd from his position as President of the Management Board of the Company, effective as of 30 May 2025. An explanatory statement outlining the reasons for the resignation was attached to the resignation and is included as an appendix to this current report.

In connection with the above, the Supervisory Board of the Company adopted a resolution on 30 May 2025 to appoint the Management Board of the Company for a new three-year term of office. The newly appointed Management Board will consist of the following individuals:

1. Mr. Michał Walczak, appointed as President of the Management Board – Chief Scientific Officer,

2. Ms. Anna Pawluk, appointed as Member of the Management Board – Chief Operating Officer,

3. Mr. Tomáš Drmota, appointed as Member of the Management Board – Chief Technology Officer.

According to the submitted declarations, each of the newly appointed members of the Management Board:

1. has full legal capacity;

2. does not conduct any business competitive with the Company, does not engage in professional activity outside the Company that would be competitive with its business, and does not participate in any competitive company as a partner in a civil law partnership, registered partnership, or capital company, nor as a member of a corporate body of a competitive legal entity;

3. has not been convicted by a final court judgment of any offenses specified in Chapters XXXIII – XXXVII of the Polish Penal Code or under Articles 587, 590, and 591 of the Polish Commercial Companies Code;

4. is not listed in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register.

The Company provides the résumés of Ms. Anna Pawluk and Mr. Tomáš Drmota as attachments to this report.
The résumé of Mr. Michał Walczak is available on the Company’s website at: https://captortherapeutics.pl/o-nas.

Furthermore, prior to the adoption of the resolution appointing the new members of the Management Board – and in order to enable the establishment of a new joint and full term of the Management Board – the Supervisory Board adopted a resolution today to dismiss Mr. Michał Walczak from his current position as Member of the Management Board – Chief Scientific Officer, thereby terminating the previous term of office of the Management Board.

The Company and its employees would like to thank Mr. Thomas Shepherd for his many years of cooperation, his significant contribution to the Company’s development, and for leading the Company into its next phase of growth. We wish him every success in his future endeavors.

Detailed legal basis: § 5 items 4 and 5 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information published by issuers of securities and on conditions under which information required by the laws of a non-member state may be recognized as equivalent.